We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Reformulated Influenza Rapid Test Made Available

By LabMedica International staff writers
Posted on 19 Mar 2019
Print article
Image: The BinaxNOW Influenza A & B Card 2 and Digival reader (Photo courtesy of Abbott).
Image: The BinaxNOW Influenza A & B Card 2 and Digival reader (Photo courtesy of Abbott).
Influenza is a viral infection of the upper respiratory system, which includes the nose, bronchial tubes, and lungs. Influenza can make people of any age ill. Although most people, including children, are ill with influenza for less than a week, some have a much more serious illness and may need to be hospitalized. Influenza may also lead to pneumonia or death.

Influenza types A and B are responsible for epidemics of respiratory illness that occur almost every winter and often lead to increased rates of hospitalization and death. Public health efforts to control the impact of influenza focus on types A and B. Influenza viruses continually mutate, which helps the virus to evade the immune system of both children and adults.

An in vitro immunochromatographic assay for the qualitative detection of influenza A and B nucleoprotein antigens in nasopharyngeal (NP) swab and nasal swab samples have now been made available. The reformulated test has been granted waived status under the Clinical Laboratory Improvements Amendments by the US Food and Drug Administration (FDA, Silver Springs, MD, USA) for use with a diagnostic reader, for the rapid detection of influenza virus.

The BinaxNOW Influenza A & B Card 2 (Abbott, Chicago, IL, USA) is available for use in hospital laboratories, emergency rooms, physician offices, walk-in clinics and urgent care centers throughout the USA. The Digival reader accurately reads and interprets BinaxNOW Influenza A & B Card 2 tests in seconds, delivering automated, objective results in a broad range of healthcare settings.

Sharon J. Bracken, MBA, senior vice president of Abbott’s rapid diagnostics division, said, “This flu season, healthcare providers need objective tests that can provide fast, accurate results to determine the best course of care for patients. The BinaxNOW Influenza A & B Card 2 adds to our strong portfolio of rapid flu tests by providing rapid and easy diagnosis, while Digival enhances healthcare providers’ confidence in results by reducing user subjectivity.”

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test
New
Amoebiasis Test
ELI.H.A Amoeba

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more